Harrow, Inc. (HROW)
After hours:
| Previous Close | 16.76 |
| Open | 16.81 |
| Bid | 16.74 x 200 |
| Ask | 16.81 x 300 |
| Day's Range | 16.56 - 17.11 |
| 52 Week Range | 7.60 - 24.19 |
| Volume | |
| Avg. Volume | 516,666 |
| Market Cap | 594.062M |
| Beta (5Y Monthly) | 0.57 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.91 |
| Earnings Date | Aug 07, 2024 - Aug 12, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 26.90 |
Business WireHarrow to Present at Two Investor Conferences in May
NASHVILLE, Tenn., May 15, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May:
Business WireHarrow Announces First Quarter 2024 Financial Results
NASHVILLE, Tenn., May 13, 2024--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the first quarter ended March 31, 2024. The Company also posted its first quarter Letter to Stockholders and corporate presentation to the "Investors" section of its website, harrow.com. The Company encourages all Harrow stockholders to review these documents, which provide additional details concerning the historical quarterly period and future expectations for t
Business WireHarrow Names Greg DiPasquale as Senior Vice President, Head of Commercial
NASHVILLE, Tenn., May 13, 2024--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, is pleased to announce the appointment of Greg DiPasquale as Senior Vice President, Head of Commercial, effective immediately. DiPasquale will oversee sales, marketing, and sales operations for Harrow’s rapidly growing portfolio of branded ophthalmic products. This new role reflects Harrow’s commitment to enhancing its leadership structure to support the Company’s continued growth. John Saharek,
